SMS Pharmaceuticals reports robust Q2FY24 operational performance
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
The collaboration brings a seamless digital experience to more formulators worldwide
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Lack of technology transfer stands out as a formidable barrier
The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
India is following a holistic and inclusive approach in alignment with the vison of Universal Health Coverage and the resolute commitment to ‘leave no one behind
Subscribe To Our Newsletter & Stay Updated